Use of rakicidins compounds for anti-clinical pathogenic anaerobic bacteria

Abstract

The invention relates to the field of biomedicine, in particular to the use of a class of Rakicidins compounds for resisting clinical pathogenic anaerobic bacteria. Pharmacodynamic experiments prove that the Rakicidins compounds have good efficacy against clinically pathogenic anaerobic bacteria, and have efficacy against diseases caused by vancomycin-resistant enterococcus infection. It can be used to treat diarrhea caused by Clostridium difficile, enteritis, digestive tract infection, oral infection or skin acne, urinary tract infection or skin and soft tissue infection and other diseases.

Description

technical field

[0001] The invention relates to the field of biomedicine, in particular to the use of a class of Rakicidins compounds for resisting clinical pathogenic anaerobic bacteria. Background technique

[0002] Rakicidin A and B were originally reported in the United States, because their 15-membered cyclic lipopeptide structure contains a rare octyl 4-amino-2,4-pentadienoate and has anti-tumor cell activity [McBrien K D , Berry R L, Lowe S E et al. Rakicidins, New Cytotoxic Lipopeptides from Micromonosporasp. Fermentation, Isolation and Characterization [J]. J Antibiot, 1995, 48:1446]. The structural formula is as follows:

[0003]

[0004] Yamazaki (2007) found that Rakicidin A has excellent hypoxic selective anti-tumor cell activity, and the anti-colon cancer HCT-8 cell activity under hypoxic conditions is 17.5 times that under normal oxygen conditions [Yamazaki Y, Kunimoto S, Ikeda D .Rakicidin A: a hypoxia-selective cytotoxin[J].Biol Pharm Bull.2007,30(2):26...

Images